A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas

PURPOSE: Bardoxolone methyl, a novel synthetic triterpenoid and antioxidant inflammation modulator, potently induces Nrf2 and inhibits NF-κB and Janus-activated kinase/STAT signaling. This first-in-human phase I clinical trial aimed to determine the dose-limiting toxicities (DLT), maximum tolerated...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Clin Cancer Res
Autores principales: Hong, David S., Kurzrock, Razelle, Supko, Jeffrey G., He, Xiaoying, Naing, Aung, Wheler, Jennifer, Lawrence, Donald, Eder, Joseph Paul, Meyer, Colin J., Ferguson, Deborah A., Mier, James, Konopleva, Marina, Konoplev, Sergej, Andreeff, Michael, Kufe, Donald, Lazarus, Hillard, Shapiro, Geoffrey I., Dezube, Bruce J.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2012
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4494099/
https://ncbi.nlm.nih.gov/pubmed/22634319
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-11-2703
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares